Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate HB0034 in Healthy Chinese Adult Participants
Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
Summary
The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose or multiple dose.
Official title: A Phase I, Randomized, Double-blind, Placebo-controlled, Single/mulit Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HB0034 in Adult Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-12-06
Completion Date
2025-11-20
Last Updated
2025-01-20
Healthy Volunteers
Yes
Conditions
Interventions
HB0034
Recombinant Humanized Anti-IL-36R Monoclonal antibody
HB0034 matching placebo
HB0034 matching Palcebo
Locations (1)
Central Hospital affiliated to Shandong First Medical University
Jinan, Shandong, China